{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:49:03Z","timestamp":1788173343347,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.schres.2024.06.047","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T23:09:00Z","timestamp":1720998540000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine"],"prefix":"10.1016","volume":"271","author":[{"given":"Petros","family":"Drosos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer Andreas","family":"Bartz-Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Ketil","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig Kl\u00e6bo","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Andreas","family":"Kroken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.06.047_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/10673229.2012.747804","article-title":"Remission in schizophrenia: critical and systematic review","volume":"20","author":"AlAqeel","year":"2012","journal-title":"Harv. Rev. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.06.047_bb0010","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.06.047_bb0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/JCP.0000000000001303","article-title":"One-year outcome and adherence to pharmacological guidelines in first-episode schizophrenia: results from a consecutive cohort study","volume":"40","author":"Drosos","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2024.06.047_bb0020","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5498\/wjp.v12.i3.521","article-title":"Trajectories of response in schizophrenia-spectrum disorders: a one-year prospective cohort study of antipsychotic effectiveness","volume":"12","author":"Drosos","year":"2022","journal-title":"World J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.06.047_bb0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.9758\/cpn.2020.18.3.434","article-title":"One-year outcome of first vs. later episode schizophrenia: a real-world naturalistic study","volume":"18","author":"Fountoulakis","year":"2020","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"4","key":"10.1016\/j.schres.2024.06.047_bb0030","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/schbul\/sbu170","article-title":"Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials","volume":"41","author":"Fusar-Poli","year":"2015","journal-title":"Schizophr. Bull."},{"issue":"10258","key":"10.1016\/j.schres.2024.06.047_bb0035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.06.047_bb0040","series-title":"Norwegian Directorate of Health (Ed.), Oslo","article-title":"Nasjonal faglig retningslinje for utredning, behandling og oppf\u00f8lging av personer med psykoselidelser (National guideline for assessment, treatment and follow-up of persons with psychotic disorders)","author":"Helsedirektoratet","year":"2013"},{"issue":"10202","key":"10.1016\/j.schres.2024.06.047_bb0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.schres.2024.06.047_bb0050","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.06.047_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"issue":"9618","key":"10.1016\/j.schres.2024.06.047_bb0060","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.06.047_bb0065","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2024.06.047_bb0070","author":"Karuna Therapeutics"},{"key":"10.1016\/j.schres.2024.06.047_bb0075","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2024.06.047_bb0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2024.06.047_bb0085","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1192\/bjp.bp.117.201475","article-title":"Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies","volume":"211","author":"Lally","year":"2017","journal-title":"Br. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2024.06.047_bb0090","doi-asserted-by":"crossref","first-page":"393","DOI":"10.31887\/DCNS.2010.12.3\/mlambert","article-title":"Remission in schizophrenia: validity, frequency, predictors, and patients\u2019 perspective 5 years later","volume":"12","author":"Lambert","year":"2010","journal-title":"Dialogues Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2024.06.047_bb0095","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/schbul\/sbm159","article-title":"Methodological issues in current antipsychotic drug trials","volume":"34","author":"Leucht","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.06.047_bb0100","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.schres.2024.06.047_bb0105","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2024.06.047_bb0110","first-page":"5","article-title":"Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat)","volume":"55 Suppl 44","author":"Lindstrom","year":"2001","journal-title":"Nord. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.06.047_bb0115","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia-an overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2024.06.047_bb0120","author":"National Cancer Institute"},{"key":"10.1016\/j.schres.2024.06.047_bb0125","series-title":"National Institute for Health and Care Excellence (Ed.), NICE Clinical Guideline 178, London","article-title":"Psychosis and schizophrenia in adults: prevention and management","author":"NICE","year":"2014"},{"key":"10.1016\/j.schres.2024.06.047_bb0130","series-title":"R: A Language and Environment for Statistical Computing","author":"R core team","year":"2021"},{"issue":"8","key":"10.1016\/j.schres.2024.06.047_bb0135","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2024.06.047_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00213-018-5133-z","article-title":"Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis","volume":"236","author":"Smith","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.06.047_bb0145","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12688\/f1000research.6699.1","article-title":"Understanding the direct and indirect costs of patients with schizophrenia","volume":"4","author":"Tajima-Pozo","year":"2015","journal-title":"F1000Res"},{"issue":"9","key":"10.1016\/j.schres.2024.06.047_bb0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424002950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424002950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T14:24:10Z","timestamp":1725719050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424002950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"alternative-id":["S0920996424002950"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.06.047","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remission in schizophrenia spectrum disorders: A randomized trial of amisulpride, aripiprazole and olanzapine","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.06.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}